References

Blackwood L, Murphy S, Buracco P European consensus document on mast cell tumours in dogs and cats. Vet Comp Oncol. 2012; 10:(3)e1-e29 https://doi.org/10.1111/j.1476-5829.2012.00341.x

Cullen JK, Boyle GM, Yap PY Activation of PKC supports the anticancer activity of tigilanol tiglate and related epoxytiglianes. Sci Rep. 2021; 11:(1) https://doi.org/10.1038/s41598-020-80397-9

de Nardi AB, Santos Horta R, Fonseca-Alves CE Diagnosis, prognosis and treatment of canine cutaneous and subcutaneous mast cell tumors. Cells. 2022; 11:(4) https://doi.org/10.3390/cells11040618

De Ridder T, Reddell P, Jones P, Brown G, Campbell J Tigilanol tiglate-mediated margins: a comparison with surgical margins in successful treatment of canine mast cell tumours. Front Vet Sci. 2021a; 8 https://doi.org/10.3389/fvets.2021.764800

De Ridder TR, Campbell JE, Burke-Schwarz C Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). J Vet Intern Med. 2021b; 35:415-429 https://doi.org/10.1111/jvim.15806

Eisenhauer EA, Therasse P, Bogaerts J New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:(2)228-247 https://doi.org/10.1016/j.ejca.2008.10.026

Elliott JW, Cripps P, Blackwood L, Berlato D, Murphy S, Grant IA Canine oral mucosal mast cell tumours. Vet Comp Oncol. 2016; 14:(1)101-111 https://doi.org/10.1111/vco.12071

Garrett LD Canine mast cell tumors: diagnosis, treatment, and prognosis. Vet Med (Auckl). 2014; 5:49-58 https://doi.org/10.2147/VMRR.S41005

Latifi M, Skinner OT, Schroeder MM, Mickelson MA Fascial plane mapping for superficial tumor resection in dogs. Part II: Forelimb. Vet Surg. 2022; 51:(1)79-87 https://doi.org/10.1111/vsu.13689

Saunders H, Thomson MJ, Connell K, Bridges JP, Chau L Evaluation of a modified proportional margin approach for complete surgical excision of canine cutaneous mast cell tumours and its association with clinical outcome. Vet Comp Oncol. 2021; 19:(4)604-615 https://doi.org/10.1111/vco.12630

Schroeder MM, Skinner OT Fascial plane mapping for superficial tumor resection in dogs. Part I: Neck and trunk. Vet Surg. 2022; 51:(1)68-78 https://doi.org/10.1111/vsu.13569

Selmic LE, Ruple A A systematic review of surgical margins utilized for removal of cutaneous mast cell tumors in dogs. BMC Vet Res. 2020; 16:(1) https://doi.org/10.1186/s12917-019-2227-8

Shoop SJ, Marlow S, Church DB Prevalence and risk factors for mast cell tumours in dogs in England. Canine Genet Epidemiol. 2015; 2 https://doi.org/10.1186/2052-6687-2-1

Treating mast cell tumours in first opinion practice: is it time to put down the knife?

02 January 2023
10 mins read
Volume 28 · Issue 1
Figure 7. a. Measurement of area to be treated before use of tigilanol tiglate. b. Appearance of site post sloughing at 10 days post tigilanol tiglate. c. Appearance 1 month post intratumoural injection of tigilanol tiglate.
Figure 7. a. Measurement of area to be treated before use of tigilanol tiglate. b. Appearance of site post sloughing at 10 days post tigilanol tiglate. c. Appearance 1 month post intratumoural injection of tigilanol tiglate.

Abstract

Georgie Hollis, Vet Wound Library, discusses some of the challenges faced following surgical resection of mast cell tumours and explores the potential benefits and risks associated with a non-surgical approach using intratumoural injection of tigilanol tiglate.

Mast cell tumours account for up to 21% of all canine tumours presenting to veterinary practice (Shoop et al, 2015). The diverse range of inflammatory and angiogenic properties made possible through degranulation means that not only do symptoms range widely but so does the level of risk and aggression.

Grading of mast cell tumours allows for planning for surgery to clear a lateral and fascial margin relative to the potential for the tumour to spread and metastasise.

Resolution is recommended through full resection, using proportional margins and appropriate anti-inflammatories and chemo-therapeutics to reduce tumour size, as well as the risks associated with degranulation of tumour cells.

Management of mast cell tumours aims for complete resolution while preserving enough viable tissue to close the deficit according to Halsted's principles of surgical technique (Hunt, 2012) (Table 1 ) and in keeping with the aims of wound healing in Table 2.

Register now to continue reading

Thank you for visiting UK-VET Companion Animal and reading some of our peer-reviewed content for veterinary professionals. To continue reading this article, please register today.